Ember Therapeutics Broadens Brown Fat Small Molecule Drug Discovery Portfolio, Secures Exclusive License Options to Intellectual Property for Three Small Molecule Targets

Published: Oct 04, 2012

BOSTON--(BUSINESS WIRE)--Ember Therapeutics, Inc., a company harnessing breakthroughs in brown fat biology and insulin sensitization to revolutionize the treatment of metabolic disease, today announced that it has secured exclusive option rights to intellectual property for three key small molecule targets – retinaldehyde dehydrogenase 1 (Aldh1a1), thioesterase superfamily member 1 (Them1), and TRPV4.

Back to news